Specify a stock or a cryptocurrency in the search bar to get a summary
Kymera Therapeutics Inc
KYMRKymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts. Address: 200 Arsenal Yards Boulevard, Watertown, MA, United States, 02472
Analytics
WallStreet Target Price
53.93 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures KYMR
Dividend Analytics KYMR
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History KYMR
Stock Valuation KYMR
Financials KYMR
Results | 2019 | Dynamics |